To determine whether suppression of TFEB1 reversed chemoresistance of ovarian cancer cells, we prepared HeyA8-MDR, a paclitaxel-resistant cell line derived from HeyA8, and A2780-CP, a cisplatin-resistant cell line derived from A2780. Here, CP is linked to ovarian carcinoma.